Brokerages Set Humana Inc. (NYSE:HUM) Target Price at $510.63

Shares of Humana Inc. (NYSE:HUMGet Rating) have earned a consensus rating of “Moderate Buy” from the nineteen brokerages that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $512.39.

HUM has been the topic of several analyst reports. Wells Fargo & Company increased their price target on shares of Humana from $512.00 to $514.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 25th. lowered shares of Humana from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 29th. Sanford C. Bernstein initiated coverage on shares of Humana in a research report on Thursday, May 26th. They set a “market perform” rating and a $506.00 price target on the stock. SVB Leerink increased their price objective on shares of Humana from $535.00 to $540.00 and gave the company an “outperform” rating in a research note on Thursday, July 28th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Humana from $450.00 to $514.00 in a research note on Thursday, July 28th.

Humana Stock Performance

Shares of NYSE:HUM opened at $478.50 on Thursday. The company’s 50 day moving average price is $485.80 and its two-hundred day moving average price is $457.63. Humana has a 12-month low of $351.20 and a 12-month high of $504.99. The firm has a market cap of $60.55 billion, a PE ratio of 19.53, a PEG ratio of 1.46 and a beta of 0.77. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.73.

Humana (NYSE:HUMGet Rating) last posted its quarterly earnings results on Wednesday, July 27th. The insurance provider reported $8.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.67 by $1.00. The business had revenue of $23.66 billion for the quarter, compared to analyst estimates of $23.44 billion. Humana had a net margin of 3.52% and a return on equity of 18.42%. The firm’s revenue for the quarter was up 14.6% on a year-over-year basis. During the same quarter last year, the business posted $6.89 EPS. Equities research analysts predict that Humana will post 24.85 earnings per share for the current year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 28th. Stockholders of record on Friday, September 30th will be paid a dividend of $0.7875 per share. This represents a $3.15 annualized dividend and a dividend yield of 0.66%. The ex-dividend date of this dividend is Thursday, September 29th. Humana’s payout ratio is currently 12.86%.

Hedge Funds Weigh In On Humana

Several large investors have recently modified their holdings of the business. Tcwp LLC bought a new position in Humana during the first quarter worth $25,000. Castleview Partners LLC raised its stake in Humana by 46,704.0% during the second quarter. Castleview Partners LLC now owns 11,701 shares of the insurance provider’s stock worth $25,000 after buying an additional 11,676 shares during the last quarter. Jones Financial Companies Lllp bought a new position in Humana during the second quarter worth $29,000. WFA of San Diego LLC acquired a new stake in Humana in the second quarter worth $30,000. Finally, Riverview Trust Co acquired a new stake in Humana in the first quarter worth $32,000. Institutional investors own 93.50% of the company’s stock.

Humana Company Profile

(Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.